![]() ![]() These data support the development of MW3321 as a monotherapy or cocktail against SARS-CoV-2-related diseases.Īfter its emergence in December 2019, the ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused devastating consequences to human health and the global economy. Moreover, MW3321 exhibits a typical hIgG1 pharmacokinetic and safety profile in cynomolgus monkeys. MW3321 could effectively reduce viral burden in hACE2-transgenic mice challenged with either wild-type or Delta SARS-CoV-2 strains through viral neutralization and Fc-mediated effector functions. ![]() Escape mutation experiments using replicating SARS-CoV-2 pseudovirus show that escape mutants were not generated until passage 6 for MW3321, which is much more resistant to escape mutation compared with another clinical staged SARS-CoV-2 neutralizing mAb MW3311. MW3321 retains full neutralization activity to all tested 12 variants that have arisen in the human population, which are assigned as VOC (Variants of Concern) and VOI (Variants of Interest) due to their impacts on public health. In this work, we comprehensively characterize the breadth and efficacy of SARS-CoV-2 RBD-targeting fully human monoclonal antibody (mAb) MW3321. Neutralization antibodies targeting SARS-CoV-2 could provide immediate protection after SARS-CoV-2 infection, especially for the most vulnerable populations. Ideal SARS-CoV-2 therapeutic antibodies would have high potency in viral neutralization against several emerging variants. Therapeutics against variants of SARS-CoV-2 are urgently needed. Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and have consistently replaced the previous dominant variant. 4Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.3State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China. ![]() 2Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.1Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.P values less than 0.001 are given three asterisks, and P values less than 0.0001 are given four asterisks.Wen Jiang 1 † Zherui Zhang 2 † Yuhe Zhu 3 † Ben Chen 1 Chunying Gu 1 Zhiyan Liu 1 Xukai Zhang 1 Hualong Xiong 3 Yanan Zhang 2 Bin Zheng 1 Rongjuan Wang 1,4 Shasha Jiao 1,4 An Wang 1 Tianying Zhang 3 Jinchao Zhang 1 Shuang Wang 1,4* Bo Zhang 2* Gang Li 1* Xun Gui 1* Choose how many digits you want to see after the decimal point, up to 15.P values less than 0.001 are summarized with three asterisks, and P values less than 0.0001 are summarized with four asterisks. The now classic GraphPad method which reports four digits after the decimal point with a leading zero (0.1234).All P values less than 0.001 are summarized with three asterisks, with no possibility of four asterisks. The NEJM (New England Journal of Medicine) style, which shows three digits and includes the leading zero (0.123).The APA (American Psychological Association) style, which shows three digits but omits the leading zero (.123).Most of Prism's analyses report P values, and now all these analyses let you choose how to report P values. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |